Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VRNA
- Price
- 57.71
- Stock movement up
- +3.78 (7.01%)
- Company name
- Verona Pharma PLC ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.72B
- Ent value
- 4.64B
- Price/Sales
- 719.45
- Price/Book
- 36.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -18.56%
- 1 year return
- 254.70%
- 3 year return
- 127.99%
- 5 year return
- 71.24%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VRNA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 719.45 |
| Price to Book | 36.19 |
| EV to Sales | 706.54 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 81.83M |
| EPS (TTM) | -1.89 |
| FCF per share (TTM) | -1.27 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.56M |
| Gross profit (TTM) | 5.28M |
| Operating income (TTM) | -155.61M |
| Net income (TTM) | -153.91M |
| EPS (TTM) | -1.89 |
| EPS (1y forward) | -0.76 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 80.41% |
| Operating margin (TTM) | -2370.63% |
| Profit margin (TTM) | -2344.75% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 336.04M |
| Net receivables | 16.81M |
| Total current assets | 364.25M |
| Goodwill | 545.00K |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.02M |
| Total assets | 381.82M |
| Accounts payable | 6.83M |
| Short/Current long term debt | 122.31M |
| Total current liabilities | 27.95M |
| Total liabilities | 251.33M |
| Shareholder's equity | 130.49M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -103.80M |
| Capital expenditures (TTM) | 90.03K |
| Free cash flow (TTM) | -103.89M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -117.95% |
| Return on Assets | -40.31% |
| Return on Invested Capital | -60.98% |
| Cash Return on Invested Capital | -41.16% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 54.28 |
| Daily high | 57.90 |
| Daily low | 53.69 |
| Daily Volume | 960K |
| All-time high | 69.63 |
| 1y analyst estimate | 47.29 |
| Beta | 0.42 |
| EPS (TTM) | -1.89 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 25 Apr 2025 |
Downside potential
Loading...
Downside potential data
| VRNA | S&P500 | |
| Current price drop from All-time high | -17.12% | -12.89% |
| Highest price drop | -89.71% | -56.47% |
| Date of highest drop | 18 Mar 2020 | 9 Mar 2009 |
| Avg drop from high | -46.95% | -11.07% |
| Avg time to new high | 30 days | 12 days |
| Max time to new high | 1170 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.72B
Marketcap category
Mid-cap
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Employees
79
Website
Investor relations
-
SEC filings
CEO
David S. Zaccardelli
Country
USA
City
London
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page